{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:15:24Z","timestamp":1788830124306,"version":"build-2803163510"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Although infliximab has been recommended for the second-line treatment of seronegative spondyloarthropathy- or juvenile idiopathic arthritis-related uveitis, the issue of its systemic efficacy and safety in a broader diversity of refractory noninfectious uveitis is debatable. To assess the short-term and relatively long-term efficacy of infliximab in refractory noninfectious uveitis, we performed a systematic review and meta-analysis of observational studies.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> PubMed, Cochrane Library, EMBASE, and Wanfang Med Online were systematically searched from January 2005 to March 2020. Two investigators independently assessed eligibility. Data were independently collected by two investigators. The pooled proportions were estimated with patients for intraocular inflammation control and improvement of visual acuity. Pooled proportions with 95% credible intervals were computed. Study homogeneity was investigated using <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> statistics to quantify the percentage of variation across studies. To pool the results, the Mantel\u2013Haenszel fixed-effects or random-effects models were used.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Of 2316 studies identified, 16 unique studies with 509 unique participants were included in the meta-analysis. The pooled proportions of intraocular inflammation control reached 92% (95% CI: 87%\u201398%; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>: 1%; p=0.42) and 95% (95% CI: 93%\u201397%; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>: 0%; p=0.91) in groups of \u22646- and \u226512-month follow-up durations. During the relatively long follow-up period, the pooled proportions of maintaining visual acuity stable or increasing at least one line reached 99% (95% CI: 96%\u2013100%; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>: 0%; p=0.54) in the involved eyes. The corticosteroid-sparing effect of infliximab was also well demonstrated, with the proportion of corticosteroid-sparing success reaching 85.5% (112\/131). Besides, about serious adverse events, 2.6% (13\/500) of patients experienced hypersensitivity reactions, 2.4% (12\/500) of patients experienced serious infections, 1.8% (9\/500) of patients experienced autoimmune diseases, and 0.6% (3\/500) of patients experienced neoplasia.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> This meta-analysis provided evidence that infliximab might be a promising choice in controlling inflammatory activity, gaining visual acuity, and sparing corticosteroid use with relatively few side effects when applied in treating refractory noninfectious uveitis.<\/jats:p><jats:p><jats:bold>Systematic Review Registration<\/jats:bold>: [website], identifier [registration number]<\/jats:p>","DOI":"10.3389\/fphar.2021.620340","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T05:02:35Z","timestamp":1631768555000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["The Efficacy and Safety of Infliximab in Refractory Noninfectious Uveitis: A Meta-Analysis of Observational Studies"],"prefix":"10.3389","volume":"12","author":[{"given":"Anji","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huini","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guancui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linqian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zepeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiquan","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/acr.2387110.1002\/art.40885","article-title":"2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis","volume":"71","author":"Angeles-Han","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ajo.2017.03.029","article-title":"Randomized Controlled Trial Evaluating a Standardized Strategy for Uveitis Etiologic Diagnosis (ULISSE)","volume":"178","author":"de Parisot","year":"2017","journal-title":"Am. J. Ophthalmol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.preteyeres.2011.06.005","article-title":"Understanding Uveitis: the Impact of Research on Visual Outcomes","volume":"30","author":"de Smet","year":"2011","journal-title":"Prog. Retin. Eye Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.22336\/rjo.2018.16","article-title":"The Use of Biologic Therapies in Uveitis","volume":"61","author":"Duica","year":"2018","journal-title":"rjo"},{"key":"B5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00296-009-1213-z","article-title":"One Year Study of Efficacy and Safety of Infliximab in the Treatment of Patients with Ocular and Neurological Beh\u00e7et's Disease Refractory to Standard Immunosuppressive Drugs","volume":"31","author":"Giardina","year":"2011","journal-title":"Rheumatol. Int."},{"key":"B6","first-page":"3","article-title":"One Year in Review 2019: Beh\u00e7et's Syndrome","author":"Hatemi","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF- : Structure, Function and Interaction with Anti-TNF Agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am. J. Ophthalmol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2017.08.007","article-title":"Immunosuppression for the Uveitides","volume":"125","author":"Jabs","year":"2018","journal-title":"Ophthalmology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/s0002-9394(00)00659-0","article-title":"Guidelines for the Use of Immunosuppressive Drugs in Patients with Ocular Inflammatory Disorders: Recommendations of an Expert Panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am. J. Ophthalmol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2147\/dddt.S166092","article-title":"Update in Treatment of Uveitic Macular Edema","volume":"13","author":"Koronis","year":"2019","journal-title":"Dddt"},{"key":"B12","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1136\/postgradmedj-2017-134891","article-title":"Uveitis: a Sight-Threatening Disease Which Can Impact All Systems","volume":"93","author":"Krishna","year":"2017","journal-title":"Postgrad. Med. J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000336183","article-title":"The Philosophy of Treatment of Uveitis: Past, Present and Future","volume":"51","author":"Kruh","year":"2012","journal-title":"Dev. Ophthalmol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ophtha.2013.07.019","article-title":"Infliximab for the Treatment of Refractory Noninfectious Uveitis","volume":"121","author":"Kruh","year":"2014","journal-title":"Ophthalmology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"650","DOI":"10.3390\/jfb6030650","article-title":"Intraocular Implants for the Treatment of Autoimmune Uveitis","volume":"6","author":"Lee","year":"2015","journal-title":"Jfb"},{"key":"B16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000336676","article-title":"The Gold Standard of Noninfectious Uveitis: Corticosteroids","volume":"51","author":"LeHoang","year":"2012","journal-title":"Dev. Ophthalmol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","article-title":"Expert Panel Recommendations for the Use of Anti-tumor Necrosis Factor Biologic Agents in Patients with Ocular Inflammatory Disorders","volume":"121","author":"Levy-Clarke","year":"2014","journal-title":"Ophthalmology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1007\/s10067-015-2989-8","article-title":"Anti-Tnf\u03b1 Agents and Methotrexate in Spondyloarthritis Related Uveitis in a Chinese Population","volume":"34","author":"Lian","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/ecco-jcc\/jjv096","article-title":"Infliximab-Related Infusion Reactions: Systematic Review","volume":"9","author":"Lichtenstein","year":"2015","journal-title":"Eccojc"},{"key":"B20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3109\/09273948.2011.633205","article-title":"Infliximab and Adalimumab for Uveitis","volume":"20","author":"Martel","year":"2012","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B21","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/09273948.2016.1236968","article-title":"Efficacy of Anti-TNF-\u03b1 Therapy for the Treatment of Non-infectious Uveitis: A Retrospective Study of 21 Patients","volume":"26","author":"Mercier","year":"2018","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B22","doi-asserted-by":"publisher","first-page":"705","DOI":"10.5301\/ejo.5000278","article-title":"Review on the Worldwide Epidemiology of Uveitis","volume":"23","author":"Miserocchi","year":"2013","journal-title":"Eur. J. Ophthalmol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.berh.2006.03.008","article-title":"Uveitis","volume":"20","author":"Mu\u00f1oz-Fern\u00e1ndez","year":"2006","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jaapos.2019.02.006","article-title":"Successful Treatment with Infliximab after Adalimumab Failure in Pediatric Noninfectious Uveitis","volume":"3","author":"Noy","year":"2019","journal-title":"J. AAPOS"},{"key":"B25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/bf00163549","article-title":"The Natural History of Uveitis","volume":"14","author":"Nussenblatt","year":"1990","journal-title":"Int. Ophthalmol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term Side Effects of Glucocorticoids","volume":"15","author":"Oray","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1080\/14740338.2019.1692810","article-title":"Safety of Systemic Therapy for Noninfectious Uveitis","volume":"18","author":"Ormaechea","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"B28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/btt.S41477","article-title":"Update on the Use of Systemic Biologic Agents in the Treatment of Noninfectious Uveitis","volume":"8","author":"Pasadhika","year":"2014","journal-title":"Biologics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.anpedi.2012.01.024","article-title":"Sarcoidosis simulando una histiocitosis no Langerhans, tratada con antagonistas del factor de necrosis tumoral \u03b1","volume":"77","author":"Petiti Martin","year":"2012","journal-title":"Anales de Pediatr\u00eda"},{"key":"B30","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.ophtha.2012.05.048","article-title":"Infliximab Treatment of Patients with Birdshot Retinochoroidopathy","volume":"3","author":"Pichaporn","year":"2013","journal-title":"Ophthalmology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10354-015-0344-y","article-title":"Anti-TNF in Rheumatoid Arthritis: an Overview","volume":"165","author":"Radner","year":"2015","journal-title":"Wien Med. Wochenschr"},{"key":"B32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.semarthrit.2015.05.010","article-title":"Anti-TNF-\u03b1 Therapy in Refractory Uveitis Associated with Sarcoidosis: Multicenter Study of 17 Patients","volume":"45","author":"Riancho-Zarrabeitia","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1002\/art.40568","article-title":"The Eyes Have it","volume":"70","author":"Rosenbaum","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"w20025","DOI":"10.4414\/smw.2019.20025","article-title":"Treatment of Chronic Non-infectious Uveitis and Scleritis","volume":"149","author":"Rossi","year":"2019","journal-title":"Swiss Med. Wkly"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2018-312767","article-title":"Long-term Efficacy and Tolerability of TNFalpha Inhibitors in the Treatment of Non-infectious Ocular Inflammation: an 8-year Prospective Surveillance Study","author":"Sharma","year":"2019","journal-title":"Br. J. Ophthalmol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/ard.2006.065441","article-title":"Use of Infliximab in Juvenile Onset Rheumatological Disease-Associated Refractory Uveitis: Efficacy in Joint and Ocular Disease","volume":"66","author":"Sharma","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/acr.20404","article-title":"Prevention of Flare Recurrences in Childhood-Refractory Chronic Uveitis: an Open-Label Comparative Study of Adalimumab versus Infliximab","volume":"63","author":"Simonini","year":"2011","journal-title":"Arthritis Care Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1093\/rheumatology\/ken298","article-title":"Loss of Efficacy during Long-Term Infliximab Therapy for Sight-Threatening Childhood Uveitis","volume":"47","author":"Simonini","year":"2008","journal-title":"Rheumatology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/archopht.125.7.895","article-title":"Infliximab Therapy for the Treatment of Refractory Ocular Inflammatory Disease","volume":"125","author":"Sobrin","year":"2007","journal-title":"Arch. Ophthalmol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of Observational Studies in EpidemiologyA Proposal for Reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"Jama"},{"key":"B42","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.prostaglandins.2018.09.004","article-title":"Inflammation and CB2 Signaling Drive Novel Changes in the Ocular Lipidome and Regulate Immune Cell Activity in the Eye","volume":"139","author":"Toguri","year":"2018","journal-title":"Prostaglandins & Other Lipid Mediators"},{"key":"B43","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000336186","article-title":"Corticosteroid-sparing Agents: New Treatment Options","volume":"51","author":"Tomkins-Netzer","year":"2012","journal-title":"Dev. Ophthalmol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1111\/imj.14215","article-title":"The Use of Biologic Agents in the Management of Uveitis","volume":"49","author":"Trivedi","year":"2019","journal-title":"Intern. Med. J."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1080\/09273948.2016.1196713","article-title":"A Focus on the Epidemiology of Uveitis","volume":"26","author":"Tsirouki","year":"2018","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B46","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.jaapos.2008.08.007","article-title":"Retrospective Analysis of Children with Uveitis Treated with Infliximab","volume":"12","author":"Tugal-Tutkun","year":"2008","journal-title":"J. Am. Assoc. Pediatr. Ophthalmol. Strabismus"},{"key":"B47","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","article-title":"Efficacy of Anti-TNF Alpha in Severe And\/or Refractory Beh\u00e7et's Disease: Multicenter Study of 124 Patients","volume":"62","author":"Vallet","year":"2015","journal-title":"J. Autoimmun."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/art.39667","article-title":"Infliximab versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study from the French Uveitis Network","volume":"68","author":"Vallet","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00281-019-00758-z","article-title":"Resolution of Uveitis","volume":"41","author":"Wildner","year":"2019","journal-title":"Semin. Immunopathol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/09273948.2019.1606256","article-title":"Comparison of the Treatment Results for Beh\u00e7et Uveitis in Patients Treated with Infliximab and Interferon","volume":"28","author":"Yal\u00e7indag","year":"2020","journal-title":"Ocul. Immunol. Inflamm."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.620340\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T05:02:39Z","timestamp":1631768559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.620340\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":50,"alternative-id":["10.3389\/fphar.2021.620340"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.620340","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,16]]},"article-number":"620340"}}